Influenza A virus vaccine H5N1 - Chengdu Kanghua Biological Products

Drug Profile

Influenza A virus vaccine H5N1 - Chengdu Kanghua Biological Products

Alternative Names: H5N1 Influenza Vaccine - Chengdu Kanhua Biological Products; Split virion influenza vaccine - Chengdu Kanghua Biological Products

Latest Information Update: 24 Sep 2015

Price : $50

At a glance

  • Originator Chengdu Kanghua Biological Products
  • Class Influenza A virus H5N1 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Influenza A virus H5N1 subtype

Most Recent Events

  • 24 Sep 2015 Chengdu Kanhua Biological Products completes clinical develoment of H5N1 influenza vaccine before September 2015 (Chengdu Kanhua Biological Products website, September 2015)
  • 04 Sep 2015 Clinical trials in Influenza-A virus H5N1 subtype in China (Parenteral) before September 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top